CB1 antagonists have been assayed effectively for obesity, but unwanted affective disorders induced by its administration motivated its market withdrawal [8]; however, the discovery of the pro-lipogenic role of the ECS has motivated active research toward an understanding of its physiological importance in the development of obesity, as well as a search for additional pharmacological targets/interventions capable of modulating its activity [9]. This evidence concerns the gene CNR1 and obesity disorder.